Immune recovery in tumor microenvironment of TP53-mutated AML following venetoclax combination therapy
The BCL-2 inhibitor venetoclax combined with the hypomethylating agent azacitidine or with low-dose cytarabine significantly improves response rates and overall survival (OS) for newly diagnosed unfit and relapsed/refractory (R/R) acute myeloid leukemia (AML) patients. We retrospectively analyzed ou...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , , , , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Elsevier
2026-05-01
|
| Rangatū: | Heliyon |
| Ngā marau: | |
| Urunga tuihono: | http://www.sciencedirect.com/science/article/pii/S2405844026004202 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|